Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the company will expand the position of the company to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications. Initiator Pharma will be in San Francisco to present the company at business and investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference January 8 to 11.
In September 2023 Initiator announced that the drug candidates, pudafensine and IP2018, had showed significant efficacy in preclinical models for Female Sexual Dysfunction (FSD) and that the company was reviewing the potential to extend the clinical indications for the drug candidates, to include FSD. During the fourth quarter 2023 a strategic review of the FSD opportunity has been completed. Based on the data obtained in the preclinical models, and a commercial assessment, the management and board of directors have decided to build on the strong data obtained from the Phase II clinical trials in male ED and expand the position of Initiator Pharma to a broader Sexual Health Franchise, offering great life cycle management and significant revenue and earning opportunities. Initiator will present its extended opportunity at business and investor meetings in connection with the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
“I am excited to be in San Francisco for the J.P. Morgan Healthcare week and to present our extended business opportunity. We are bringing with us, two strong drug candidates, pudafensine and IP2018, that both have demonstrated statistically significant and clinically relevant data in our recently completed trials. In addition, the recent strategic review of the FSD opportunity is an obvious kicker for the overall utility and value of our assets,” said Claus Elsborg Olesen, CEO of Initiator Pharma.